CD68 and neoplasm: Another study by Ou Yang et al. in 2014 evaluated the use of a new prognostic test (BCAM test) that could be used in all tumor stages and subtypes, consisting of the analysis of expression of FGD3-SUSD3 metagene, other attractor metagenes (CIN, MES, LYM, END, CD68, DNAJB9 and CXCL12), tumor size and the number of positive lymph nodes.